Product References — Human Serum

Innovative Research's Pooled Normal Human Serum was recently used in the following study: Interactions between ibrutinib and anti-CD20 antibodies; competing effects on the outcome of combination therapyM Skarzynski, CU Niemann, YS Lee, S Martyr, I Maric - Clinical Cancer Research, 2015...for two hours in the presence of 33% normal human serum (Innovative Research, Novi, MI) as a source of complement. The proportion of lysed CD19...

Innovative Research's Pooled Normal Human Serum was recently used in the following study: The Effect of PON1 Enhancers on Reducing Acetylcholinesterase Inhibition Following Organophosphate Anticholinesterase Exposure in RatsEC Meek, HW Chambers, RB Pringle, JE Chambers - Toxicology, 2015... Commercially available pooled human serum was obtained from Innovative Research, Novi, MI. 2.1. Organophosphate substrate synthesis. ...

Innovative Research's Pooled Normal Human Serum was recently used in the following study: Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaquesK Patton, S Aslam, C Shambaugh, R Lin, D Heeke… - Vaccine, 2015... Test samples and positive control sera (IPLA-SER, Innovative Research, Novi MI) were heat inactivated, initially diluted 1:10, and 3-fold serially diluted in virus growth medium (VGM), comprised of minimum essential medium containing Earle's balance salt solution, 1× non ...

Innovative Research's Single Donor Human Serum was recently used in the following study: MATERIALS AND METHODS PatientsSP accession No, N accession No, D Glycoprotein - Genome... Samples were stored at 70C. Purchased sera from 60 healthy donors (Innovative Research Inc., Novi, MI, USA) were included as controls. This study was approved by the Institutional Review Board of Severance Hospital, Yonsei University College of Medicine, Seoul, Korea...

Innovative Research's Pooled Complement Human Serum was recently used in the following study: Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59H Zhang, AS Verkman - Journal of Autoimmunity, 2014Human complement (Innovative Research, Novi, MI) and NMO-IgG were then added in Hank's buffer, and cells were incubated at 28 C for 2 h. Cytotoxicity was measured by the Alamar Blue assay (Invitrogen). 2.5. NMO-IgG binding.